Dr. A. (Alan) Abdulla

• PK/PD antibiotics
• Critically ill patients
• Therapeutic drug monitoring (TDM)

• Hospital Pharmacist | 1/2018 - present
  Erasmus University Medical Center, Rotterdam, the Netherlands.

• PhD candidate | 1/2018 - 9/2022
  Erasmus University Medical Center, Rotterdam, the Netherlands. Thesis subject: Dose individualization of Beta-lactams and Ciprofloxacin in ICU patients.

• Resident Hospital Pharmacy | 12/2013 - 12/2017
  Erasmus University Medical Center, Rotterdam, the Netherlands.

• Pharmacist | 9/2012 - 11/2013
  Martini Hospital, Groningen, the Netherlands.

A complete overview of publications can be found on Pubmed.

• Supervision of various thesis projects of MSc. Pharmacy and Medical students.
• Different educational activities for the following groups: residents, nurses, medical students, pharmacy technicians, clinical pharmacists.

GRANTS

• 2020 – present: An exploratory PK/PD study of cefotaxime, ceftazidime, ceftriaxone, cefuroxime, flucloxacillin and meropenem in PICU patients: is there a need for more precision dosing? Funding: Erasmus University Medical Center MRace PhD Grant (€150K), co-applicant.
• 2019 – 2023: Dose individualization of Beta-lactam antibiotics in ICU patients: to TDM or not to TDM and the effects on patient outcome. Funding: The Netherlands Organisation for Health Research and Development ZonMw (€500K), co-writer.
• 2018 - 2022 Expansion of DOLPHIN trail with additional research centers. Funding: Stichting de Merel (€50K), co-applicant.
• 2018 - 2022 PK/PD of Beta-lactam and Fluoroquinolone antibiotics in critically ill patients. Funding: Erasmus University Medical Center MRace PhD Grant (€150K), co-applicant.
  
  

  AWARDS AND HONOURS

• 2019 Dutch Platform for Pharmaceutical Research - Best publication in 2018, Opwijrda ward.
• 2018 Residents association (AAV Erasmus MC) - Best Abstract Award.
• 2017 Dutch Association for Intensive Care (NVIC) - Best Abstract oral presentation Award.